Literature DB >> 14517746

The fibrinolytic system in children.

Manuela Albisetti1.   

Abstract

The fibrinolytic system comprises a cascade of serine proteinase activation events that culminate in the generation of plasmin and, subsequently, degradation of fibrin. Although all components of the fibrinolytic system are present at birth, plasma concentrations of key components in infants and children differ physiologically from those in adults. Until the age of 6 months, plasma concentrations of plasminogen and alpha (2)-antiplasmin are decreased to 50% and 80% of adult values, respectively, while plasma concentrations of tissue-type plasminogen activator are decreased and plasminogen activator inhibitor-1 are increased throughout childhood. In addition, the rate of plasmin generation in newborns and the overall fibrinolytic activity during childhood are decreased compared with adults. Strong evidence suggests that age-dependent differences in the fibrinolytic system critically influence the effectiveness and safety of thrombolytic agents. In addition, recent studies suggest that impaired fibrinolysis may play an important role in the pathogenesis of several diseases such as venous and arterial diseases and vasculitis, which are associated with both endothelial cell damage and increased thrombotic risk. This article will discuss the ontogenic features of the fibrinolytic system in children and summarize the available information on the effect of developmental fibrinolysis on both the course of specific disease states and the response to thrombolytic therapy in children.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14517746     DOI: 10.1055/s-2003-42585

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  9 in total

1.  Pharmacokinetics of ε-Aminocaproic Acid in Neonates Undergoing Cardiac Surgery with Cardiopulmonary Bypass.

Authors:  Michael P Eaton; George M Alfieris; Dawn M Sweeney; Ronald E Angona; Jill M Cholette; Charles Venuto; Brian Anderson
Journal:  Anesthesiology       Date:  2015-05       Impact factor: 7.892

2.  Hypoxia-inducible factor-1 drives annexin A2 system-mediated perivascular fibrin clearance in oxygen-induced retinopathy in mice.

Authors:  Bihui Huang; Arun B Deora; Kai-Li He; Kang Chen; Guangzhi Sui; Andrew T Jacovina; Dena Almeida; Peng Hong; Paul Burgman; Katherine A Hajjar
Journal:  Blood       Date:  2011-07-25       Impact factor: 22.113

Review 3.  Developmental hemostasis in the neonatal period.

Authors:  Vicente Rey Y Formoso; Ricardo Barreto Mota; Henrique Soares
Journal:  World J Pediatr       Date:  2022-01-04       Impact factor: 2.764

4.  Population pharmacokinetics of epsilon-aminocaproic acid in infants undergoing craniofacial reconstruction surgery.

Authors:  P A Stricker; A F Zuppa; J E Fiadjoe; L G Maxwell; E M Sussman; E Y Pruitt; T K Goebel; M R Gastonguay; J A Taylor; S P Bartlett; M S Schreiner
Journal:  Br J Anaesth       Date:  2013-01-25       Impact factor: 9.166

5.  Enoxaparin therapy for arterial thrombosis in infants with congenital heart disease.

Authors:  Joe Bontadelli; Alexander Moeller; Markus Schmugge; Thomas Schraner; Oliver Kretschmar; Urs Bauersfeld; Vera Bernet-Buettiker; Manuela Albisetti
Journal:  Intensive Care Med       Date:  2007-06-07       Impact factor: 17.440

6.  Stroke: thrombolysis in childhood arterial ischemic stroke.

Authors:  Lori C Jordan
Journal:  Nat Rev Neurol       Date:  2009-09       Impact factor: 42.937

7.  Alterations in the Coagulation System during Major Visceral Surgery in Children.

Authors:  Hayarpi H Kordjian; Mads Nybo; Niels Qvist
Journal:  Surg Res Pract       Date:  2014-02-26

Review 8.  Neonatal ECMO.

Authors:  Cornelia Heleen Van Ommen; Cindy E Neunert; Meera B Chitlur
Journal:  Front Med (Lausanne)       Date:  2018-10-25

9.  Postoperative pulmonary embolism in a three year old with Klippel-Trenaunay syndrome.

Authors:  Jana Hudcova; Monica Kleinman; Daniel Talmor
Journal:  Int Med Case Rep J       Date:  2009-01-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.